Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Synagis TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: vutrisiran
Brand name
(ARTG)
: SYNAGIS palivizumab (rmc) 50 mg / 0.5 mL solution for injection vialDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (CHD). (See Clinical Trials).
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Intramuscular
- Clear or slightly opalescent, sterile solution.
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Store in Original Container
- Shelf lifetime is 3 Years.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient vutrisiran
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Respiratory syncytial virus (RSV) FAQs | NCIRS
Respiratory syncytial virus (RSV) is a common virus that can infect people of all ages. It is most serious in infants, young children and older adults.
Read more on National Centre for Immunisation Research and Surveillance (NCIRS) website
Bronchiolitis - myDr.com.au
Bronchiolitis is a viral chest infection that affects mainly babies under a year old and may cause breathing difficulties, wheeze and a cough.
Read more on MyDoctor website
RSV - Immunisation Coalition
About RSV RSV Symptoms How RSV Spreads RSV Complications RSV Prevention RSV Treatment More RSV Information About RSV Respiratory Syncytial Virus (RSV) is a common virus which is very contagious and infects most children before they turn two years of age
Read more on Immunisation Coalition website
Top results
RSV Guide - Immunisation Coalition
About RSV Cause And Transmission How Is RSV Treated? RSV Prevention Pharmaceutical Interventions RSV In Young Children RSV In Adults Download the Guide pdf About RSV Respiratory syncytial virus (RSV) is a common virus that infects the airways and lungs
Read more on Immunisation Coalition website
Vaccination During Pregnancy Guide - Immunisation Coalition
About Pregnancy And Vaccinations Whooping Cough Vaccination During Pregnancy Influenza Vaccination During Pregnancy COVID-19 Vaccination During Pregnancy RSV Vaccination During Pregnancy RSV Prevention In High-Risk Infants Download the Guide pdf About Pregnancy And Vaccinations People are particularly vulnerable during pregnancy and should receive the influenza vaccine, the whooping cough (pertussis) vaccine, and now a COVID-19 vaccine and an RSV vaccine to protect themselves and their baby
Read more on Immunisation Coalition website
